Analysis of PD-L1 Immunohistochemistry Results for Different Sampling Procedures of Non-small Cell Lung Carcinoma. Can We Use Cell Blocks for Evaluation of PD-L1?

Year 2022, Volume: 12 Issue: 3, 215 - 222, 15.12.2022

Esin Kaymaz Haldun Umudum

Abstract

Aim: Current guidelines recommend evaluating the expression of PD-L1 immunohistochemically in most tumors, especially lung cancer. However, it is not easy to evaluate the immunohistochemical staining of PD-L1 because of the tumor heterogeneity. Therefore, we aim to evaluate the different patterns of PD-L1 in the lung’s nonsmall cell carcinoma and the relationship with clinicopathological features. We also wanted to see if cell blocks obtained from cytology materials can be an alternative for PD-L1 immunohistochemistry.
Material and Method: We retrospectively analyzed the immunohistochemical patterns of PD-L1 performed between 2018 and 2019. Biopsy/aspiration procedure of tumors, tumor type, patient’s age, and gender were reviewed. Positive tumor cells (percentage) were categorized according to density and distribution as negative (<1%), low expression (1–49%), and high expression (>50%).
Results: Material adequacy was found to be satisfactory in evaluating PD-L1 in the cases of cell blocks. Positive staining with PDL1 was detected even with a small number of tumor cells in the cell block. For optimal evaluation of PD-L1 expression in the cell block, the tumor cell ratio of 10% is significant (p=0.002). The cases with negative PD-L1 expression mostly belonged to small biopsy samples (48.3%). However, the difference in PD-L1 expression in histological and cytological samples was insignificant (p=0.79). Besides this, expression of PD-L1 was negative in almost half of the cases (48.3%) diagnosed with squamous cell carcinoma. In adenocarcinoma cases, the PD-L1 expression rate was between 1–49 % in more than half (51.8%) of them. The difference in histological subtype was not significant in PD-L1 staining (p=0.009).
Conclusion: In conclusion, we can use cell blocks for immunohistochemical evaluation of PD-L1 expression. Analysis of PD-L1 staining in cytological and histological tissue samples may be a guide for other studies.

Keywords

PD-L1, tumor, lung carcinoma, cell block

References

• 1. Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets T her 2016; 12 (9):5023-39.
• 2. Shi SJ, Wang LJ, Wang GD, Guo ZY, Wei M, Meng YL, et al. B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PLoS One 2013; 8(10):e76012.
• 3. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21(1):24–33.
• 4. Allison JP. Immune checkpoint blockade in cancer therapy: the 2015. Lasker-DeBakey Clinical Medical Research Award. JAMA. 2015; 314(11):1113–4.
• 5. National Comprehensive Cancer Network (2020). NCCN Clinical Practice Guidelines in Oncology, Small Cell Lung Cancer.
• 6. Zou, Y., Xu, L., Tang, Q. You Q, Wang X, Ding W, et al. Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples. BMC Cancer 2020; 20:344
• 7. Bubendorf L, Lantuejoul S, de Langen AJ, Thunnissen E. Nonsmall cell lung carcinoma: Diagnostic difficulties in small biopsies and cytological specimens. Eur Respir Rev. 2017;26: 170007.
• 8. Munari E, Zamboni G, Marconi M, Sommaggio M, Brunelli M, Martignoni G, et al. PD-L1 expression heterogeneity in nonsmall cell lung cancer: evaluation of small biopsies reliability. Oncotarget. 2017;8(52):90123–31.
• 9. Haragan A, Field JK, Davies MPA, Escriu C, Gruver A, Gosney JR. Heterogeneity of PD-L1 expression in non-small cell lung cancer: implications for specimen sampling in predicting treatment response. Lung Cancer. 2019;134: 79–84.
• 10. Wei Y, Zhao Q, Gao Z, Lao XM, Lin WM, Chen DP. The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy. J Clin Invest. 2019;129(8):3347–60.
• 11. Bulutay P, Fırat P. (2021). Assessment: Küçük Hücreli Dışı Akciğer Karsinomlarında Farklı Koruyucu Solüsyonlar ile Oluşturulan Hücre Bloklarında PD-L1 Ekspresyonu. Paper presented at the 9th National Cytopathology Congress. 26-28 March 2021.
• 12. Kulac İ, Aydin A, Bulutay P, Firat P. Efficiency of Cytology Samples for PD-L1 Evaluation and Comparison with Tissue Samples. Turk Patoloji Derg. 2020;36(3):205-10.
• 13. Petrelli F, Maltese M, Tomasello G, Conti B, Borgonovo K, Cabiddu M, et al. Clinical and molecular predictors of PD-L1 expression in non-Small-cell lung Cancer: systematic review and meta-analysis. Clin Lung Cancer. 2018;19(4):315–22.
• 14. Pan Y, Zheng D, Li Y, Cai X, Zheng Z, Jin Y, et al. Unique distribution of programmed death ligand 1 (PD-L1) expression in east Asian non-small cell lung cancer. J Thorac Dis. 2017;9(8):2579–86.